The Situation
Single-product company with fewer than 25 employees looking to launch a new CNS biosimilar in the US.
The Solution
EVERSANA deployed NAM team prior to product market availability, communicating evidence-based value prop. to targeted payers & PBMs.
Tactical plan refined based on payer feedback in time for launch.
The Results
75% formulary “covered or better” within 6 months of launch.